日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Technology

Chinese firm Insilico to test AI-developed drug

By Cheng Yu | chinadaily.com.cn | Updated: 2021-03-05 14:26
Share
Share - WeChat
[Photo/IC]

Insilico Medicine, a Chinese investors-backed company that uses artificial intelligence to develop new drugs, said that its chemical compound candidate is likely to enter into clinical trials by the end of this year, according to its top executives.

"We expect our chemical compound candidate to start its first clinic trial by the end of the end before the second and third trials," said Ren Feng, chief science officer at Insilico Medicine.

"(Once finished), it will be the first time that the world uses AI to find new targets, discover new compounds, and makes into the clinical period, which will be a milestone," Ren said.

The company announced recently that it has found a new therapeutic target and potential therapy candidate for idiopathic pulmonary fibrosis, or IPF, through AI technologies. It said that the potential therapy has been validated in preclinical tests in human tissue and animal models of IPF.

"This is the first case where AI identified a novel target and designed a preclinical candidate for a very broad disease indication…and we need to have many enabling AI technologies that help us understand and manipulate human biology in other chronic diseases," said Alex Zhavoronkov, founder and CEO of Insilico Medicine.

According to him, the entire research and development process only takes 18 months and costs only one-tenth of a similar project.

Industry insiders said the development of a new drug is a complex and resource-consuming process, which usually costs pharmaceutical companies an average of $2.6 billion and up to 10 years of research and development.

"Customers are beginning to pay more attention to healthcare and they are more aware of the use of AI after the COVID-19 pandemic. AI is set to play a greater role in driving the medical and healthcare industry," said Kaifu-Lee, chairman and CEO of venture capital firm Sinovation Ventures, which invested into Insilico Medicine.

"The bottom layer of AI is the digital evolution. In whatever field that can become digital, it is possible to use data science and AI to help such area to increase its value," he said.

Liang Yingyu, managing partner of Qiming Venture Partners, said that AI image recognition was the first large-scale application of AI in the medical field, and then expanded drug research and development.

"But there are still many areas where AI is not engaged into. The prospect of AI medical industry enjoys broad prospect," she noted.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产激情91久久精品导航 | 超碰97人人艹| 一级毛片播放 | 久久国内精品 | 亚洲不卡视频在线 | 国产精品美女久久久久久久久久久 | 四虎影片国产精品8848 | 超级97碰碰碰碰久久久久最新 | 天天看天天摸色天天综合网 | 精品国产一区二区三区成人影院 | 亚洲精品国产成人 | 91在线网| 成人一级片在线观看 | 男人天堂网www | 国产福利视频在线观看 | 九九视频九九热 | 久久草在线视频免费 | 亚洲一区二区三区四 | 成人国产精品一区二区毛片在线 | 色综合网站在线 | 一区二区三区中文字幕 | 午夜丰满少妇高清毛片1000部 | 亚洲精品无 | 日韩一区二区福利 | 一区二区三区免费看 | 国产欧美日韩一区 | 99这里只有精品视频 | 欧美日韩午夜 | 国产专区在线播放 | 丁香婷婷六月综合交清 | 天天操操操操操操 | 亚洲91 | 国产精品久久久久久久久久久新郎 | 天天爆操 | jiucao视频在线观看 | 免费观看成人拍拍拍1000视频 | 免费日本毛片 | 亚洲精品视 | 久久婷婷在线 | 小明永久免费视频 | 91精品视频免费在线观看 |